EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery

Hui Qu iD, QianXue Wei iD, Wen Gu iD, Zhenhua Du iD, Xiuqin Li iD, Yu Xia iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Hui Qu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the clinical outcomes of elderly patients with advanced ovarian cancer who did not undergo surgery and received chemotherapy with or without maintenance therapy.

Methods

We retrospectively analyzed the clinical data of 15 patients with advanced high-grade serous ovarian cancer who were treated at our hospital between 2018 and 2023. These patients either had multiple comorbidities or refused surgery. Data collected included patient demographics, treatment regimens, chemotherapy cycles, clinical response, progression-free survival (PFS), and overall survival (OS).

Results

The median age of the patients was 73 years (range, 50-86 years). Fourteen patients received platinum-based chemotherapy combined with paclitaxel or liposomal doxorubicin, with or without bevacizumab, for 3 to 6 cycles. Twelve patients who achieved disease control received PARP inhibitor maintenance therapy. The overall response rate (ORR) was 80.0%, or 12/15 patients achieved partial response (PR); nobody achieved complete response. The disease control rate (DCR) was 100%. The median PFS1 was 19.0 months (95% CI, 11.85-26.15), and the median PFS2 was 10 months. The 3-year OS rate was 65.2%, with a median OS of 57.0 months (95% CI, 13.00-100.99).

Conclusions

Chemotherapy with or without bevacizumab, followed by PARP inhibitor maintenance therapy, is a viable alternative for elderly or surgically ineligible patients with advanced ovarian cancer. The findings of this study should be considered exploratory and require validation through large-scale studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedRetrospective StudiesAged, 80 and overMiddle AgedBevacizumabPaclitaxel

Stichwörter der Autor:innen

advanced ovarian cancerchemotherapycomorbidityelderlymaintenance therapyoverall survival

Substanzen

BevacizumabPaclitaxel

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.

ORCID-Profile: Hui Qu, QianXue Wei, Wen Gu, Zhenhua Du, Xiuqin Li, Yu Xia

Zitieren

APA

Qu, H., Wei, Q., Gu, W., Du, Z., Li, X., & Xia, Y. (2025). Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery. The Oncologist. https://doi.org/10.1093/oncolo/oyaf290

Vancouver

Qu H, Wei Q, Gu W, Du Z, Li X, Xia Y. Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery. The Oncologist. 2025. doi:10.1093/oncolo/oyaf290

BibTeX
@article{Qu2025,
  author = {Qu, Hui and Wei, QianXue and Gu, Wen and Du, Zhenhua and Li, Xiuqin and Xia, Yu},
  title = {Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf290}
}
Kostenlos starten →